文献速递鼻科

鼻内糖皮质激素不导致眼部改变:系统综述与荟萃分析

Intranasal Corticosteroids Do Not Lead to Ocular Changes: A Systematic Review and Meta-analysis.
PubMed 文献 · Laryngoscope · 2018-09-19

该系统综述与荟萃分析评估鼻内糖皮质激素(INCS)是否增加成人鼻炎患者眼压升高、青光眼或后囊下白内障风险。纳入10项随机对照试验共2226例患者,结果显示INCS与安慰剂相比眼压升高的相对风险为2.24(95%CI 0.68-7.34),绝对发生率增加0.8%(95%CI 0%-1.6%),12个月内两组均无青光眼病例,后囊下白内障绝对发生率增加0.02%(95%CI -0.3%-0.4%)。结论认为INCS不显著增加眼压升高或后囊下白内障风险,但青光眼是真正需关注的临床不良事件,未来研究应正式评估青光眼而非以眼压为替代指标。

要点

  • INCS与安慰剂相比眼压升高相对风险2.24(95%CI 0.68-7.34),无统计学显著性。
  • INCS组眼压升高绝对发生率增加0.8%(95%CI 0%-1.6%)。
  • 12个月内两组均无青光眼病例,后囊下白内障绝对发生率增加0.02%(95%CI -0.3%-0.4%)。

核心结论

  • 成人鼻炎患者使用INCS不显著增加眼压升高或后囊下白内障风险,但青光眼是真正需关注的临床不良事件。

研究设计与样本

  • 系统综述与荟萃分析,由两名医学图书馆员检索文献,纳入10项随机对照试验,共2226例患者。

主要发现

  • INCS组与安慰剂组相比眼压升高的相对风险为2.24(95%CI 0.68-7.34)。
  • INCS组眼压升高绝对发生率增加0.8%(95%CI 0%-1.6%)。
  • 12个月时安慰剂组和INCS组青光眼病例均为零。
  • 后囊下白内障绝对发生率增加0.02%(95%CI -0.3%-0.4%)。

关键数值与推荐

  • 眼压升高定义为眼压超过20 mm Hg。
  • 纳入标准为讨论鼻内类固醇用于鼻炎及其对眼压、白内障或青光眼影响的随机对照试验。

临床怎么用

  • 成人鼻炎患者使用INCS时无需过度担忧眼压升高或后囊下白内障风险。
  • 临床应关注青光眼的发生,但12个月内未见病例报告。
  • 未来研究应正式评估青光眼而非仅用眼压作为替代指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The safety and efficacy of intranasal corticosteroids (INCS) are well established, but there remains apprehension that INCS could lead to systemic side effects, as with oral steroids. The objective of this systematic review was to assess whether the use of INCS lead to increased intraocular pressure (IOP) above 20 mm Hg, glaucoma, or formation of posterior subcapsular cataracts in adult patients with rhinitis. METHODS: Two medical librarians searched the published literature for records discussing the use of "nasal steroids" in "rhinitis" and their effect on "intraocular pressure," "cataracts," or "glaucoma." RESULTS: A total of 484 studies were identified, and 10 randomized controlled trials met our inclusion criteria. Meta-analysis of 2,226 patients revealed that the relative risk of elevated IOP in those who received INCS was 2.24 (95% confidence interval [CI]: 0.68 to 7.34) compared to placebo. The absolute increased incidence of elevated IOP in patients using INCS compared to placebo was 0.8% (95% CI: 0% to 1.6%). There were zero cases of glaucoma in both placebo and INCS groups at 12 months. The absolute increased incidence of developing a posterior subcapsular cataract was 0.02% (95% CI: -0.3% to 0.4%). CONCLUSIONS: Use of INCS is not associated with a significant risk of elevating IOP or developing a posterior subcapsular cataract in patients with allergic rhinitis. Presence of glaucoma, however, is the real clinical adverse event of concern. There were zero reported cases of glaucoma at 12 months. Future studies should formally evaluate for glaucoma rather than use IOP measures as a surrogate. Laryngoscope, 129:6-12, 2019.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Valenzuela CV, Liu JC, Vila PM, et al. Intranasal Corticosteroids Do Not Lead to Ocular Changes: A Systematic Review and Meta-analysis. Laryngoscope. 2018. PMID: 30229924. doi:10.1002/lary.27209

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。